SOBETIROME

/static/temp/default.svg

Search structure


Synonyms	GC-1 QRX-431 Sobetirome
Status
Molecule Category	UNKNOWN
UNII	XQ31741E9Q
EPA CompTox	DTXSID60891557


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QNAZTOHXCZPOSA-UHFFFAOYSA-N
Smiles	Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)c(C(C)C)c1
InChI	InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H24O4
Molecular Weight	328.41
AlogP	4.19
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	6.0
Polar Surface Area	66.76
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	24.0

Assay Description	Organism	Bioactivity	Reference
Half-maximum activation of human Thyroid hormone receptor alpha-1 (hTRalpha1)	None	45.0 nM
Binding affinity against human Thyroid hormone receptor alpha-1 (hTRalpha1) using radiolabeled T3	Homo sapiens	1.8 nM
Binding affinity of compound was determined against Thyroid hormone receptor alpha1	None	0.66 nM
Half-maximum activation of human Thyroid hormone receptor beta 1 (hTRbeta1)	Homo sapiens	7.0 nM
Binding affinity against human Thyroid hormone receptor beta 1 (hTRbeta1) using radiolabeled T3	Homo sapiens	0.1 nM
Binding affinity of compound was determined against thyroid hormone receptor beta 1	None	0.1 nM
Displacement of [125I]3,5,3'-triiodo-L-thyronine from His-tagged human recombinant TRalpha1 by scintillation proximity assay	Homo sapiens	1.09 nM
Displacement of [125I]3,5,3'-triiodo-L-thyronine His-tagged human recombinant TRbeta1 by scintillation proximity assay	Homo sapiens	0.32 nM
Binding affinity to human TRalpha1	Homo sapiens	2.5 nM
Binding affinity to human TRbeta1	Homo sapiens	0.2 nM
Agonist activity at recombinant His6-tagged THR-beta (unknown origin) expressed in Escherichia coli BL21(DE3) co-expressing RXR preincubated for 30 mins assessed as biotin-GRIP1 peptide recruitment by HTRF assay	Homo sapiens	18.0 nM
Agonist activity at recombinant His6-tagged THR-alpha (unknown origin) expressed in Escherichia coli BL21(DE3) co-expressing RXR preincubated for 30 mins assessed as biotin-GRIP1 peptide recruitment by HTRF assay	Homo sapiens	3.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	9.12 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	11.93 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	7.819 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.16 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.09 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.09 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.16 %

Cross References

Resources	Reference
ChEBI	79988
ChEMBL	CHEMBL107400
DrugBank	DB07425
FDA SRS	XQ31741E9Q
Guide to Pharmacology	2639
KEGG	C15618
PDB	B72
PubChem	9862248
SureChEMBL	SCHEMBL282119
ZINC	ZINC000013475083

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).